Traders Purchase Large Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) saw unusually large options trading activity on Thursday. Traders bought 2,884 call options on the stock. This is an increase of approximately 245% compared to the average volume of 835 call options.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new stake in shares of Reviva Pharmaceuticals in the 2nd quarter valued at approximately $31,000. BluePointe Capital Management LLC grew its stake in shares of Reviva Pharmaceuticals by 354.7% during the first quarter. BluePointe Capital Management LLC now owns 47,185 shares of the company’s stock worth $45,000 after purchasing an additional 36,807 shares in the last quarter. NewEdge Advisors LLC purchased a new position in Reviva Pharmaceuticals in the first quarter valued at $58,000. Ameriprise Financial Inc. acquired a new stake in Reviva Pharmaceuticals in the fourth quarter valued at $84,000. Finally, Geode Capital Management LLC lifted its holdings in Reviva Pharmaceuticals by 6.9% during the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after buying an additional 29,063 shares during the last quarter. Hedge funds and other institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Trading Up 35.1%

NASDAQ:RVPH opened at $0.49 on Friday. Reviva Pharmaceuticals has a 12-month low of $0.25 and a 12-month high of $4.28. The firm has a market cap of $33.82 million, a PE ratio of -0.75 and a beta of -0.08. The stock has a fifty day moving average price of $0.44 and a 200 day moving average price of $0.63.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03. Equities analysts forecast that Reviva Pharmaceuticals will post -0.97 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on RVPH. D. Boral Capital decreased their price target on shares of Reviva Pharmaceuticals from $3.00 to $2.00 and set a “buy” rating for the company in a research note on Friday, September 19th. Chardan Capital began coverage on Reviva Pharmaceuticals in a research note on Monday. They set a “buy” rating and a $2.00 price target on the stock. Wall Street Zen upgraded shares of Reviva Pharmaceuticals to a “sell” rating in a report on Saturday, August 16th. Maxim Group lowered their price target on shares of Reviva Pharmaceuticals from $5.00 to $2.00 and set a “buy” rating for the company in a research report on Friday, August 15th. Finally, Benchmark reduced their price objective on shares of Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating for the company in a research note on Monday, September 15th. Eight analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $4.86.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.